Myovant Sciences Ltd. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 11 rows in 2018. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2018-12-17: Reporting owner Sablich Kim; Form 4; Security Employee Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2018-11-06: Reporting owner Torti Frank; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2018-09-20: Reporting owner POTTER MYRTLE S; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2018-08-31: Reporting owner Sebelius Kathleen; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2018-12-17 | Sablich Kim Officer (Chief Commercial Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +133,500 133,500 owned after | $17.28 exercise price | 2018-12-18 | |
| 2018-11-06 | Torti Frank Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +45,000 45,000 owned after | $22.83 exercise price | 2018-11-08 | |
| 2018-09-20 | POTTER MYRTLE S Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +45,000 45,000 owned after | $26.17 exercise price | 2018-09-24 | |
| 2018-08-31 | Sebelius Kathleen Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +22,500 22,500 owned after | $24.25 exercise price | 2018-09-04 | |
| 2018-08-31 | Curran Terrie Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +22,500 22,500 owned after | $24.25 exercise price | 2018-09-04 | |
| 2018-08-31 | Altmeyer Mark Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +22,500 22,500 owned after | $24.25 exercise price | 2018-09-04 | |
| 2018-07-23 | GUINAN MARK Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +45,000 45,000 owned after | $19.71 exercise price | 2018-07-24 | |
| 2018-04-16 | Lang Matthew Officer (General Counsel & Corp. Secy.) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +87,050 87,050 owned after | $21.87 exercise price | 2018-04-18 | |
| 2018-04-16 | Seely Lynn Director, Officer (Principal Executive Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +248,450 248,450 owned after | $21.87 exercise price | 2018-04-18 | |
| 2018-04-16 | KARBE FRANK Officer (Principal Fin'l & Accounting) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +114,690 114,690 owned after | $21.87 exercise price | 2018-04-18 | |
| 2018-04-16 | Arjona Ferreira Juan Camilo Officer (Chief Medical Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +87,050 87,050 owned after | $21.87 exercise price | 2018-04-18 |